What is the recommended treatment plan for a patient with a prostate-specific antigen level >2000 ng/mL who has been started on relugolix and bicalutamide?

Management of Extremely Elevated PSA (>2000 ng/mL) on Relugolix and Bicalutamide

The current regimen of relugolix plus bicalutamide is suboptimal and should be immediately upgraded to include a novel hormonal agent (abiraterone, enzalutamide, apalutamide, or darolutamide) in place of bicalutamide, with strong consideration for adding docetaxel chemotherapy if the patient is fit and has high-volume metastatic disease. 1

Critical Assessment of Current Regimen

The combination of relugolix (an oral GnRH antagonist providing ADT) with bicalutamide (a first-generation antiandrogen) represents an outdated approach for metastatic hormone-sensitive prostate cancer, particularly with a PSA >2000 ng/mL which indicates high disease burden. 1

• Bicalutamide monotherapy or in combination with ADT is only FDA-approved for Stage D2 metastatic disease at 50 mg daily, and the 150 mg dose is explicitly not approved for use alone or with other treatments. 2
• Bicalutamide may provide some benefit in metastatic patients with PSA ≤400 ng/mL, but your patient's PSA >2000 ng/mL far exceeds this threshold, making bicalutamide particularly inadequate. 3

Recommended Treatment Intensification

For Fit Patients with High-Volume Disease (≥4 bone metastases with ≥1 beyond vertebral bodies/pelvis, OR visceral metastases):

Triplet therapy is the preferred approach:

• ADT (continue relugolix) + docetaxel + abiraterone-prednisone is the strongest recommendation for fit patients with high-volume metastatic disease, offering the greatest survival benefit. 1
• Alternative triplet: ADT (relugolix) + docetaxel + darolutamide is also strongly recommended with equivalent evidence quality. 1
• Docetaxel should be administered for 6 cycles (75 mg/m² every 3 weeks) during the initial treatment phase. 1

For Patients Who Cannot Tolerate Chemotherapy or Have Low-Volume Disease:

Doublet therapy with a novel hormonal agent:

• Replace bicalutamide with abiraterone 1,000 mg daily plus prednisone 5 mg daily (strong recommendation, high-quality evidence). 1
• Alternative options include enzalutamide 160 mg daily or apalutamide 240 mg daily or darolutamide 600 mg twice daily, all with strong evidence for survival benefit when combined with ADT. 1

Relugolix-Specific Considerations

Relugolix can be safely continued as the ADT backbone:

• Relugolix achieves rapid testosterone suppression (castrate levels within 4 days) and maintains sustained castration in 96.7% of patients through 48 weeks, superior to leuprolide (88.8%). 4
• Relugolix demonstrates a 54% lower risk of major adverse cardiovascular events compared to leuprolide, making it particularly advantageous in patients with cardiovascular comorbidities. 4
• Relugolix has been studied in combination with abiraterone, apalutamide, and enzalutamide with no new safety concerns and maintained efficacy. 5, 6, 7
• Real-world data shows >97% adherence to oral relugolix with PSA responses equivalent to clinical trials. 8, 6

Monitoring Requirements for Bicalutamide (If Temporarily Continued)

If bicalutamide cannot be immediately discontinued, implement intensive hepatic monitoring:

• Measure serum transaminases (particularly ALT) before starting, at regular intervals for the first 4 months, and periodically thereafter. 2
• Immediately discontinue bicalutamide if jaundice develops or ALT rises above 2× upper limit of normal, as hepatotoxicity typically occurs within the first 3-4 months and can be fatal. 2
• Monitor PT/INR closely if patient is on anticoagulants, as bicalutamide can cause excessive prolongation leading to serious bleeding. 2

Staging and Risk Stratification Needed

Obtain imaging to determine disease volume and guide treatment intensity:

• Perform bone scan and CT abdomen/pelvis to assess for high-volume disease (≥4 bone metastases with ≥1 beyond vertebral bodies/pelvis, OR visceral metastases). 1, 9
• High-volume disease strongly favors triplet therapy with docetaxel. 1
• Consider PSMA PET imaging if available for more accurate staging. 1

Common Pitfalls to Avoid

• Do not continue bicalutamide long-term when novel hormonal agents (abiraterone, enzalutamide, apalutamide, darolutamide) have proven superior survival benefits with strong evidence. 1
• Do not use ADT alone (even with relugolix) in patients who can tolerate treatment intensification, as this results in significantly inferior outcomes. 1
• Do not delay docetaxel in fit patients with high-volume disease, as the survival benefit is most pronounced in this population and only demonstrated for de novo metastatic disease. 1
• Do not assume all novel hormonal agents are interchangeable—while all show benefit, abiraterone and enzalutamide have the most mature long-term survival data. 1

PSA Monitoring

• Measure PSA every 3 months during treatment to assess response. 2
• A rising PSA on three consecutive measurements at monthly intervals indicates progression and warrants treatment modification. 9, 2
• With appropriate intensification, expect PSA to decline by ≥90% from baseline in approximately 64-69% of patients. 8